Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
2.68
+0.34 (14.53%)
At close: May 12, 2026, 4:00 PM EDT
2.70
+0.02 (0.75%)
After-hours: May 12, 2026, 7:04 PM EDT
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Barry D. Quart Pharm.D. | CEO & Director |
| Dr. Lei Sun Ph.D. | VP of Biologics & Head of CMC |
| Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) |
| Mr. David L. Szekeres J.D. | President |
| Mr. Jeff Cohn J.D. | General Counsel & Corporate Secretary |
| Mr. Sean T. Ristine | Vice President of Human Resources |
| Ms. Kimberly J. Manhard | Executive VP & Chief Development Officer |
| Ms. Lisa Peraza CPA | Senior Vice President of Finance |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | 10-Q | cntb-20260331.htm |
| 2026-04-23 | 8-K | cntb-20260423.htm |
| 2026-03-31 | 8-K | cntb-20260331.htm |
| 2026-03-31 | 10-K | cntb-20251231.htm |
| 2026-03-30 | 8-K | cntb-20260329.htm |
| 2025-12-23 | 8-K | cntb-20251217.htm |
| 2025-11-12 | 10-Q | cntb-20250930.htm |
| 2025-09-16 | 8-K | cntb-20250916.htm |
| 2025-09-10 | POS AM | d94748dposam.htm |
| 2025-08-13 | 8-K | cntb-20250813.htm |